Preclinical Pharmacokinetic Assessment of a Promising Vasorelaxant, Analgesic, and Anti‐Inflammatory Prototype 5‐[1‐(4‐Fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) Through Selective Bioanalytical HPLC‐PDA‐Based Method
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Lanussy Porfiro de Oliveira und 10 weiteren Autor:innen. Beteiligte Einrichtung: Toxicopharmacological Studies and Research Core (NEPET-UFG), College of Pharmacy, Federal University of Goiás, Goiânia, Brazil. Hauptthemen laut MEDLINE: Tetrazoles, Analgesics, Anti-Inflammatory Agents, Pyrazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Ciência e Tecnologia, Fundação de Amparo à Pesquisa do Estado de Goiás.
Abstract (Originalsprache)
A simple and selective high‐performance liquid chromatography bioanalytical method was developed and validated to determine the pharmacokinetic parameters of 5‐[1‐(4‐fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) with promising vasorelaxant, anti‐inflammatory, and antinociceptive properties while verifying its potential hepatic enzyme induction or inhibition. Chromatographic separation was achieved using a reversed‐phase C18 column (ACE, 150 × 4.6 mm, 5 μm) with isocratic elution of a solvent mixture comprising acetonitrile and 0.2% formic acid (30:70, v/v). Detection of LQFM020 and the internal standard, piroxicam, was performed using a photodiode array detector. The method demonstrated excellent linearity ( r > 0.998), with precision and accuracy within acceptable limits [intraday precision: 6.1%, interday precision: 9.3%; intraday accuracy: 113.2%, interday accuracy: 107.3%]. Pharmacokinetic studies revealed rapid oral absorption of LQFM020 at doses of 9, 18, and 36 mg/kg, as well as following a single intravenous dose (10 mg/kg). LQFM020 exhibited an absolute bioavailability of 46%, a relatively low apparent volume of distribution, and moderate elimination rates, suggesting extensive plasma protein binding. Additionally, LQFM020 showed no significant effect on the biotransformation of compounds mediated by the cytochrome P450 CYP3A4 enzyme. In conclusion, this new bioanalytical method supports preclinical studies and provides a basis for the utility of LQFM020 as a potential drug candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Toxicopharmacological Studies and Research Core (NEPET-UFG), College of Pharmacy, Federal University of Goiás, Goiânia, Brazil.
- Department of Pharmacy, Federal University of Vales Do Jequitinhonha and Mucuri, Diamantina, Brazil.
- Department of Physiology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, Brazil.
- Nuclear Magnetic Resonance Laboratory, Institute of Chemistry, Federal University of Goiás, Goiânia, Brazil.
- Laboratory of Medicinal Pharmaceutical Chemistry, College of Pharmacy, Federal University of Goiás, Goiânia, Brazil.
ORCID-Profile: Jerônimo Raimundo de Oliveira Neto, Alessandro Carvalho Cruz
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Ciência e Tecnologia
- Fundação de Amparo à Pesquisa do Estado de Goiás
- Fundação de Apoio à Pesquisa da Universidade Federal de Goiás
Zitieren
APA
de Oliveira, L. P., de Oliveira Neto, J. R., de Oliveira, T. S., Naves, L. M., Marques, S. M., Cruz, A. C., Fajemiroye, J. O., Pedrino, G., Lião, L. M., Menegatti, R., & da Cunha, L. C. (2025). Preclinical Pharmacokinetic Assessment of a Promising Vasorelaxant, Analgesic, and Anti‐Inflammatory Prototype 5‐[1‐(4‐Fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) Through Selective Bioanalytical HPLC‐PDA‐Based Method. Biomedical Chromatography. https://doi.org/10.1002/bmc.70082
Vancouver
de Oliveira LP, de Oliveira Neto JR, de Oliveira TS, Naves LM, Marques SM, Cruz AC, et al. Preclinical Pharmacokinetic Assessment of a Promising Vasorelaxant, Analgesic, and Anti‐Inflammatory Prototype 5‐[1‐(4‐Fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) Through Selective Bioanalytical HPLC‐PDA‐Based Method. Biomedical Chromatography. 2025. doi:10.1002/bmc.70082
BibTeX
@article{deOliveira2025,
author = {de Oliveira, Lanussy Porfiro and de Oliveira Neto, Jerônimo Raimundo and de Oliveira, Thiago Sardinha and Naves, Lara Marques and Marques, Stefanne Madalena and Cruz, Alessandro Carvalho and Fajemiroye, James Oluwagbamigbe and Pedrino, Gustavo and Lião, Luciano Morais and Menegatti, Ricardo and da Cunha, Luiz Carlos},
title = {Preclinical Pharmacokinetic Assessment of a Promising Vasorelaxant, Analgesic, and Anti‐Inflammatory Prototype 5‐[1‐(4‐Fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) Through Selective Bioanalytical HPLC‐PDA‐Based Method},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70082}
}
EUVIMED